Centro Médico Austral OMI - CABA
Centro Médico Austral OMI - CABA
Montevideo 955, C1019ABS Cdad. Autónoma de Buenos Aires, Argentina
Select an option
I am a doctor
I am a sponsor
Our team
Medical staff
Cintia Novas
Guillermo Juan Carlos Streich
Natalia Schahovskoy
Johanna Ayeray Costa
Lilen Pastor
Paula Pinto
Roger Rodrigo Sanchez
Open studies
Urothelial cancer
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) - IDeate-PanTumor02 - Daiichi SankyoSee more
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 - KEYNOTE-D78 - Seagen Inc.See more
Lung cancer
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - ABBV-399 - AbbVieSee more
Solid tumors
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) - IDeate-PanTumor02 - Daiichi SankyoSee more
Endometrial Cancer
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) - IDeate-PanTumor02 - Daiichi SankyoSee more
Head and neck cancer
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) - IDeate-PanTumor02 - Daiichi SankyoSee more
Colorectal cancer
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) - IDeate-PanTumor02 - Daiichi SankyoSee more
Liver Cancer
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) - IDeate-PanTumor02 - Daiichi SankyoSee more
Gastroesophageal cancer
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) - IDeate-PanTumor02 - Daiichi SankyoSee more
Esophageal cancer
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) - IDeate-PanTumor02 - Daiichi SankyoSee more
Gastrointestinal Cancer
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) - IDeate-PanTumor02 - Daiichi SankyoSee more
Ovarian cancer
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) - IDeate-PanTumor02 - Daiichi SankyoSee more
Cervical cancer
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) - IDeate-PanTumor02 - Daiichi SankyoSee more
Bile Duct Cancer
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) - IDeate-PanTumor02 - Daiichi SankyoSee more
Breast Cancer
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) - IDeate-PanTumor02 - Daiichi SankyoSee more
Skin cancer
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) - IDeate-PanTumor02 - Daiichi SankyoSee more
Pancreatic cancer
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) - IDeate-PanTumor02 - Daiichi SankyoSee more
Cardiovascular disease
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event - AZURE-Outcomes - AstraZenecaSee more
